Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
about
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemiaMonoclonal anti-CD20 antibodies for chronic lymphocytic leukaemiaChemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphomaOfatumumab: a novel monoclonal anti-CD20 antibodyThe emerging role of ofatumumab in the treatment of chronic lymphocytic leukemiaFludarabine in the treatment of chronic lymphocytic leukemia: a reviewCombination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaChronic lymphocytic leukemia: a clinical review including Korean cohortsProfile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemiaTumor antigen-specific monoclonal antibodies and induction of T-cell immunityTargeting CD19 in B-cell lymphoma: emerging role of SAR3419Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitorsChronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatmentIdentification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugsThe shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.An update on the management of chronic lymphocytic leukaemia.Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma.Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.Alemtuzumab for B-cell chronic lymphocytic leukemia.Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaPhase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphomaChemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLLVenetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyFlavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphomaModern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroupsRole of bendamustine in the treatment of chronic lymphocytic leukemia.17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.Non-infectious pulmonary toxicity of rituximab: a systematic review.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.The spectrum of use of rituximab in chronic lymphocytic leukemiaSilencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLLRole of fludarabine in hematological malignancies.
P2860
Q24203027-BCFBF576-85B1-4C9E-90AC-82032BB79471Q24241519-4D9F2B6E-4944-44B0-BDA0-933CC0237B34Q24243100-A161758B-7886-44A8-89B2-C3E0E8781686Q24604065-1EE8FED9-4E7F-4DD6-A92C-FAE2FDDE3A74Q24617708-76FEB837-E1D3-4A0C-8845-30FB9D382433Q24645173-4E5B8ACD-A29F-40D9-BA6F-A47AA5543FE5Q24681296-FA1CBF3E-A0C3-4F48-B227-700674734947Q26752467-4E24F787-81E6-44A4-B4F0-F690428815FFQ26781163-A88BB3FA-E08E-47B4-BF15-8942264E5A78Q27009908-8EC042CF-C199-437F-A225-8AB6AA5C0206Q27027562-D7E31EFB-BB0F-4EAF-8724-19303D71079FQ28081162-EDBCFFF2-A5FD-4162-9CA9-69FEF672D663Q28082086-A35F1407-210D-4DAF-A250-1567933EE8F9Q28533669-27A4745A-BAC0-4DFE-A9BB-0B715D4B6815Q30243968-A8C0FBC5-838E-4DAD-9CCD-EDE6E86CD2F4Q30341946-D64AE1AF-E260-4475-9D3A-3B73641A5963Q33362450-16C60928-1E37-485B-BC9A-064CFDA746FDQ33375915-32A43E40-842E-4E43-BDC9-FC437F6ADD3FQ33380135-C8D374AA-B985-4430-991E-A272B33EAD98Q33382030-ACC5B417-7ACF-4D81-A526-79C084DAA099Q33385670-9F5B377E-41E4-471E-84A7-EBCBE67EC6B8Q33394947-85B1BAC9-96E7-4622-8119-C763F67BA807Q33418091-1B0A59E2-79F7-4F56-9718-8953E0BC8663Q33438428-91EABCF7-E9BD-4C67-B6FA-2313C7E0C93FQ33627721-2D13607C-7C06-458D-86D0-BFBED5CB31BDQ33691650-4321506C-4998-4911-BD21-49C9A62700ADQ33880538-29AE9909-5B82-4731-8AD2-1E39DC819C44Q33905245-CCB5EC53-86F7-43CE-BFB2-FA1E273628BDQ33913537-6F16F509-9559-4F5B-A32F-675BA39D0600Q33916026-627CE052-836C-4725-898D-3ECD528DBDB1Q33997214-14A288E0-F93A-43A0-8C77-7744092E6AB2Q34026194-E63C449F-E168-4FDA-A84C-FDA630BABEA3Q34056768-DC4D7353-FF93-417E-8B6A-26F371DF6846Q34096300-38C88636-FB4F-412C-8F1A-4AAFF40CEF8CQ34310845-74F3EE3E-EABB-4917-912E-CDADBED1EED4Q34334943-DD018A94-D33B-4B35-B1C4-2A13758CFB6CQ34440110-1021EBF1-A2B1-472F-B574-E18C6D157094Q34510030-0D393B33-04E0-4CBB-8545-477E711C0638Q34557974-6389D689-DB9A-4543-BFB8-6A94D5E74953Q34571439-127C98B4-9C32-4B61-8593-499E0B8B41F7
P2860
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Randomized phase 2 study of fl ...... mia Group B 9712 (CALGB 9712).
@ast
Randomized phase 2 study of fl ...... mia Group B 9712 (CALGB 9712).
@en
Randomized phase 2 study of fl ...... mia Group B 9712 (CALGB 9712).
@nl
type
label
Randomized phase 2 study of fl ...... mia Group B 9712 (CALGB 9712).
@ast
Randomized phase 2 study of fl ...... mia Group B 9712 (CALGB 9712).
@en
Randomized phase 2 study of fl ...... mia Group B 9712 (CALGB 9712).
@nl
prefLabel
Randomized phase 2 study of fl ...... mia Group B 9712 (CALGB 9712).
@ast
Randomized phase 2 study of fl ...... mia Group B 9712 (CALGB 9712).
@en
Randomized phase 2 study of fl ...... mia Group B 9712 (CALGB 9712).
@nl
P2093
P921
P1433
P1476
Randomized phase 2 study of fl ...... mia Group B 9712 (CALGB 9712).
@en
P2093
Bercedis L Peterson
Charles A Schiffer
James W Vardiman
Kathleen Park
Richard A Larson
Robert Jacobson
Vicki A Morrison
P356
10.1182/BLOOD-2002-04-1258
P407
P50
P577
2002-07-05T00:00:00Z